Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant 2020 Jan;26(1):e7-e15
Date
09/19/2019Pubmed ID
31526843Pubmed Central ID
PMC6942175DOI
10.1016/j.bbmt.2019.09.015Scopus ID
2-s2.0-85073734108 (requires institutional sign-in at Scopus site) 14 CitationsAbstract
The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discussion of the statistical and regulatory issues intrinsic to the development of MRD as a surrogate endpoint. In this report, we provide a summary of the workshop and focus on the integration of MRD and IP assessment into trial design and clinical practice.
Author List
Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PLAuthors
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of WisconsinMarcelo C. Pasquini MD, MS Professor in the Medicine department at Medical College of Wisconsin
Qizhen Shi MD, PhD Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Clinical Trials as TopicCongresses as Topic
Education
Hematology
Humans
Multiple Myeloma
Neoplasm, Residual
Societies, Medical
United States
